Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818053 or natasha@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
natasha@zenopa.com
+44 1494 818053

Testimonials
Within my time at Zenopa, I have found my Contractor Manager to offer the most fantastic support! The transition from my previous contract house was seamless and all the processes with Zenopa are very...
Jaz, 2012

Merck Serono increases contributions to fertility innovation fund

4 July 2012 11:16 in Pharmaceutical Company Product News


Merck Serono has increased its contributions to its Grant for Fertility Innovation (GFI) programme fund to four million euros (3.21 million pounds).

The company has committed to expanding its support for the fund in 2012/13 in order to provide greater assistance to academic centres that are conducting research into assisted reproductive technologies.

Since the launch of the scheme in 2009, Merck Serono has received around 400 applications from researchers based in more than 40 countries.

The aim of the initiative is to provide scientists with the funds to transform their innovative translational fertility research projects into concrete health solutions.

Dr Annalisa Jenkins, executive vice-president of global development and medical at Merck Serono, said: "We firmly believe that scientific collaboration that brings together researchers from across the academic and industry continuum will be the leading driver for the next wave of research and medical innovation."

Earlier this month, it was announced that Merck Serono will be participating in a private-public partnership to combat the parasitic disease schistosomiasis, in association with Astellas, TI Pharma and the Swiss Tropical and Public Health Institute.ADNFCR-8000103-ID-801400114-ADNFCR

Other news stories from 04/07/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd